Company: DVAX
Filing Date: 2025-05-19
Form Type: DFAN14A
Source: 0001193125-25-122435
Chunk: 4

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-19
Form: DFAN14A
Chunk 4
---
 leverage CpG 1018 (aka 1018 ISS) to develop drugs for: Ragweed allergy HBV prophylaxis Asthma Non- Other similar ISS adjuvants were also being developed for: Innate immunity Grass allergy HBV immunotherapy Rheumatoid arthritis Tree allergy Anthrax Peanut allergy Human viral influenza Only HBV prophylaxis after a tumultuous development path has made it across the finish line. All TWELVE other programs have failed or been suspended. This does not even count the program attempts between 2003 and today (e.g., Tdap terminated Nov 2024). This time is different is NOT a business strategy 1 DVAX S-1 filed Oct 24, 2003 5 2 Heplisav, FDA Summary Basis for Regulatory Action, https://www.fda.gov/media/109808/download (aka 1018 ISS)

After 20+ Years Of Trying, DVAX Only Has Heplisav to show for CpG 1018 CpG 1018 has already been tried in at least a dozen unique indications across over 40k patients and over two decades Since 2004 Many unique indications not comprehensive 40k+ patients NCT Number Start Date Study Status Conditions Sponsor Phases Enrollment NCT00251394 07/2004 COMPLETED Non-Hodgkin's Lymphoma Dana-Farber Cancer Institute PHASE2 30 NCT00426712 01/2006 COMPLETED Hepatitis B Dynavax Technologies Corporation PHASE1 42 NCT00403052 11/2006 TERMINATED Colorectal Neoplasms Dynavax Technologies Corporation PHASE1 14 NCT00498212 07/2007 TERMINATED Hepatitis B Dynavax Technologies Corporation PHASE2 41 NCT03934736 4/22/2019 COMPLETED End Stage Renal Disease on Hemodialysis (Diagnosis) Dynavax Technologies Corporation PHASE1 119 NCT04177355 1/13/2020 COMPLETED HIV Infections National Institute of Allergy and Infectious Diseases (NIAID) PHASE1 127 NCT04405908 6/19/2020 COMPLETED COVID-19 Clover Biopharmaceuticals AUS Pty PHASE1 166 NCT04450004 7/10/2020 COMPLETED SARS-CoV 2 Medicago PHASE1 180 NCT04487210 10/7/2020 COMPLETED COVID-19